Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease
dc.contributor.author | Metzger, Corinne E. | |
dc.contributor.author | Swallow, Elizabeth A. | |
dc.contributor.author | Stacy, Alexander J. | |
dc.contributor.author | Tippen, Samantha P. | |
dc.contributor.author | Hammond, Max A. | |
dc.contributor.author | Chen, Neal X. | |
dc.contributor.author | Moe, Sharon M. | |
dc.contributor.author | Allen, Matthew R. | |
dc.contributor.department | Anatomy and Cell Biology, School of Medicine | en_US |
dc.date.accessioned | 2020-10-30T17:10:03Z | |
dc.date.available | 2020-10-30T17:10:03Z | |
dc.date.issued | 2020 | |
dc.description.abstract | Purpose Chronic kidney disease (CKD) patients have a high incidence of fracture due in part to cortical porosity. The goal of this study was to study cortical pore infilling utilizing two rodent models of progressive CKD. Methods Exp 1: Female C57Bl/6J mice (16-week-old) were given dietary adenine (0.2%) to induce CKD for 10 weeks after which calcium water supplementation (Ca-H2O; 1.5% and 3%) was given to suppress PTH for another 4 weeks. Exp 2: Male Cy/+ rats were aged to ~30 weeks with baseline porosity assessed using in vivo μCT. A second in vivo scan followed 5-weeks of Ca-H2O (3%) supplementation. Results Exp 1: Untreated adenine mice had elevated blood urea nitrogen (BUN), parathyroid hormone (PTH), and cortical porosity (~2.6% porosity) while Ca-H2O lowered PTH and cortical porosity (0.5–0.8% porosity). Exp 2: Male Cy/+ rats at baseline had variable porosity (0.5%–10%), but after PTH suppression via Ca-H2O, cortical porosity in all rats was lower than 0.5%. Individual pore dynamics measured via a custom MATLAB code demonstrated that 85% of pores infilled while 12% contracted in size. Conclusion Ca-H2O supplementation causes net cortical pore infilling over time and imparted mechanical benefits. While calcium supplementation is not a viable clinical treatment for CKD, these data demonstrate pore infilling is possible and further research is required to examine clinically relevant therapeutics that may cause net pore infilling in CKD. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Metzger, C. E., Swallow, E. A., Stacy, A. J., Tippen, S. P., Hammond, M. A., Chen, N. X., Moe, S. M., & Allen, M. R. (2020). Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 115632. https://doi.org/10.1016/j.bone.2020.115632 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/24209 | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.bone.2020.115632 | en_US |
dc.relation.journal | Bone | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | chronic kidney disease | en_US |
dc.subject | bone | en_US |
dc.subject | cortical porosity | en_US |
dc.title | Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease | en_US |
dc.type | Article | en_US |